CAS No.:54-25-1

TOXICITY DATA with REFERENCE：

1.		sln-dmg-par 20 mmol/L		BCPCA6    Biochemical Pharmacology. 15 (1966),299.
2.		spm-rat-ipr 2 g/kg		CEFYAD    Ceskoslovenska Fysiologie. 21 (1972),278.
3.		dni-mus-ipr 3 g/kg		NEOLA4    Neoplasma. 20 (1973),243.
4.		spm-mus-ipr 5 g/kg		CEFYAD    Ceskoslovenska Fysiologie. 21 (1972),278.
5.		ivn-wmn TDLo:150 mg/kg (47D preg):TER		CLPTAT    Clinical Pharmacology and Therapeutics. 7 (1966),162.
6.		ipr-rat LD50:9400 mg/kg		TJADAB    Teratology, A Journal of Abnormal Development. 4 (1971),287.
7.		ipr-mus LD50:11,250 mg/kg		BCPCA6    Biochemical Pharmacology. 14 (1965),1517.
8.		ipr-dog LD50:3400 mg/kg		BCPCA6    Biochemical Pharmacology. 14 (1965),1537.
9.		ipr-cat LD50:2400 mg/kg		BCPCA6    Biochemical Pharmacology. 14 (1965),1537.

Consensus Reports：

EPA Genetic Toxicology Program.

SAFETY PROFILE：

Moderately toxic by intraperitoneal route. Human teratogenic effects by intravenous route: unspecified developmental abnormalities or effects on the embryo or fetus. An experimental teratogen. Experimental reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of NO_x. Used as an antineoplastic agent.
Hazard Codes: Xn
Risk Statements:
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed. 
R40:Limited evidence of a carcinogenic effect.
Safety Statements:
S22:Do not breathe dust. 
S36:Wear suitable protective clothing.

Standards and Recommendations：

 

Analytical Methods：